On February 4, 2025 Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) reported a strategic decision to discontinue all clinical trials and associated activities, including the ongoing VIO-01 trial (Press release, Valerio Therapeutics, FEB 4, 2025, View Source [SID1234650040]). This shift was decided by the board of directors in the context of the financing challenges of the Company. The Company’s cash position should enable it to finance its refocused business other the next three months. In the meantime, in addition to the reduction of its expenses, it is negotiating with its stakeholders and is seeking to reach the agreement needed to secure its financial and cash trajectory in the next twelve months.
The end of clinical trials will enable the company to focus exclusively on early-stage drug development, ensuring efficient use of available capital while maintaining a strong focus on innovation.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
As part of this transition, Valerio will cease clinical-stage operations in oncology and close its U.S. office in Lexington, MA. The company is conducting a strategic review to redefine its pipeline and long-term vision, ensuring sustainable growth and value creation for stakeholders. The Company will focus on its early-stage activities, namely the development of its single chain antibody platform, which, coupled with chemistry capabilities and oligonucleotides expertise, can open new avenues for the company.
The company will update the market as soon as the ongoing discussions with its stakeholders lead to securing a long-term financing solution to achieve its strategic development milestones.
Julien Miara, Chairperson and CEO of Valerio Therapeutics, commented:
"This decision, which will help consolidate the financial position of the company together with other actions, allows us to focus on our core strengths in early-stage research while preserving financial flexibility to drive transformative innovation. We extend our gratitude to the patients, investigators, and partners who have supported our clinical efforts and remain steadfast in our mission to develop novel therapies addressing critical unmet needs.
Valerio is committed to providing updates on its revised strategy and future plans in due course."